Infographic: The Changing Face of UK Drug Discovery by the Numbers

After Brexit, UK pharma is striving to reinvigorate drug discovery through collaboration. This infographic shows why that’s necessary.

A new report from the Association of the British Pharmaceutical Industry (ABPI) has a grim finding: the UK is beginning to lose out on global drug discovery investment compared to 10 years ago. Spending on pharmaceutical R&D in Britain has increased to £4Bn per year, but this rate is not enough to keep up with the global pace.

Consequently, the industry is shifting to focus on collaboration and open innovation, as “60% of major pharmaceutical companies have increased investment in outsourced and collaborative drug discovery work in the UK over the last 10 years, whilst simultaneously decreasing the number of in-house drug discovery lab staff,” according to the report.

Biotech stands to be one of the main beneficiaries of this new collaboration-driven model as one of the best pools of potential partners for pharma.

Featured Image: imagedb.com/shutterstock.com

Advancements in antimalarial drug discovery and development

This webinar explores how recent innovations are transforming antimalarial drug discovery and development. Discover how advanced screening techniques, novel compound development, and data-driven decision-making empower researchers to accelerate candidate selection, overcome parasite resistance, and enhance therapeutic efficacy across the R&D pipeline.

Register now